Salt Substitute Offers a Cheap Way to Cut Stroke Risk at Scale, Study Finds
August 29th 2021A simple intervention to get people to use salt substitute and cut their stroke risk—along with other cardiovascular events—has implications for developing countries with diets high in salt that have high rates of chronic disease.
Read More
Dr Deepak L. Bhatt Underscores Sotagliflozin Benefits Seen in SOLOIST, SCORED
August 29th 2021In patients with heart failure and diabetes, sotagliflozin can lower glucose quite well, even when patients are facing suboptimal glomerular filtration rates, noted Deepak L. Bhatt, MD, MPH, of Brigham and Women’s Hospital and Harvard Medical School.
Read More
REDUCE-IT vs STRENGTH: Still Missing Pieces in the Omega-3 Puzzle
August 29th 2021In a paper being presented during ESC Congress 2021, authors from the University of Copenhagen use a registry to mimic 2 well-known trials, finding explanations for some, but not all, of the gap in risk reduction between them.
Read More
Dr Børge G. Nordestgaard on Unexplained Omega-3 Mysteries in REDUCE-IT vs STRENGTH
August 29th 2021Both REDUCE-IT and STRENGTH recruited people with very high triglycerides and tested different formulations of omega-3 fatty acids, but the results were different. About 12% of the difference can be explained, noted Børge G. Nordestgaard, MD, DMSc, Department of Clinical Biochemistry, Herlev and Gentofte Hospital, Copenhagen University Hospital, but 13% cannot be, given that REDUCE-IT had a 25% reduced risk of atherosclerotic cardiovascular disease.
Read More
Dr Bertram Pitt: Finerenone Works Across the Spectrum of Cardiovascular Disease
August 29th 2021There was a reduction in both the need for dialysis and progression to end-stage renal disease; finerenone was really well tolerated, stated Bertram Pitt, MD, professor of medicine emeritus, University of Michigan School of Medicine.
Read More
Dr Dipti Itchhaporia: There Is Potential for Finerenone Combination Treatment
August 28th 2021With finerenone being a targeted therapy, data show there may be an additive cardiorenal benefit when it is coadministered with a sodium glucose co-transporter 2 inhibitor, noted Dipti Itchhaporia, MD, FACC, FAHA, FESC, president of the American College of Cardiology.
Read More
Dr Rudolf de Boer Discusses Encouraging Trial Results on SGLT2 Use in HFpEF
August 28th 2021Sodium glucose co-transporter 2 (SGLT2) inhibitor use in patients with heart failure with preserved ejection fraction (HFpEF) has generated great enthusiasm, noted Rudolf de Boer, MD, PhD, clinical cardiologist and professor of translational cardiology, University Medical Center Groningen, the Netherlands.
Read More
Dr Stefan Anker: Empagliflozin Improves HFpEF-Related Outcomes Regardless of Diabetes Status
August 27th 2021The composite end point of cardiovascular death and heart failure hospitalization was reduced by 21%, which is highly statistically significant and clinically meaningful, noted Stefan Anker, MD, PhD, FESC, principal investigator of EMPEROR-Preserved.
Read More
Dr Deepak L. Bhatt on Increasing the Use of SGLT2 Inhibitors in Clinical Practice
August 25th 2021There are incredible data for sodium-glucose co-transporter 2 (SGLT2) inhibitors, and this is a great class of medicines that is vastly underutilized, stated Deepak L. Bhatt, MD, MPH, executive director of interventional cardiovascular programs at Brigham and Women’s Hospital Heart & Vascular Center and professor of medicine at Harvard Medical School.
Read More
EMPEROR-Preserved, and the “Very Elegant” SGLT2 Inhibitors, to Highlight ESC Congress
August 25th 2021The lack of approved treatments for heart failure with preserved ejection fraction has represented a significant unmet need for a condition that affects 50% of patients with heart failure, including large subgroups, such as older women.
Read More
Dr Manan Pareek Shares Data From the Cardiac Complications Registry in Patients With COVID-19
September 6th 2020Providers need to focus on detecting and treating cardiovascular complications in at-risk patients, and not get lost in the fact they have COVID-19, said Manan Pareek, MD, PhD, FAHA, FESC, an internal medicine hospital resident at the Yale University School of Medicine.
Read More
Dr Javed Butler Discusses Cardiologists' Roles in T2D Management
September 4th 2020If you change the narrative and package SGLT-2 inhibitors as a form of cardiovascular risk modulation, cardiologists may be more likely to get involved in diabetes management, said Javed Butler, MD, MPH, MBA, chairman for the Department of Medicine at the University of Mississippi.
Read More
Dr Deepak Bhatt Discusses Cardiologists' Role in COVID-19
September 2nd 2020During the surge of the pandemic in the Northeast, we saw about a 40% reduction in cardiovascular admissions, while there was a higher rate of mortality among patients who came in, said Deepak L. Bhatt, MD, MPH, of Brigham and Women’s Hospital Heart & Vascular Center and Harvard Medical School.
Read More
Dr Antonio Pelliccia: Those With CVD Need to Stay Active During Pandemic
September 1st 2020It is imperative individuals with cardiovascular diseases remain active despite COVID-19 lockdowns, said Antonio Pelliccia, MD, senior consultant and chief of cardiology at the Institute of Sports Medicine and Science, of the Italian National Olympic Committee.
Read More
Dr John McMurray: The Next Step for SGLT 2 Inhibitors in Patients With HF Is Implementation
September 1st 2020It's a great time to be a doctor treating patients with heart failure, given the development of 2 fantastic new treatments within the space of 5 years, said John McMurray, MD, FRCP, FESC, professor of medical cardiology in the Institute of Cardiovascular and Medical Sciences at the University of Glasgow.
Read More
Dr Antonio Pelliccia Discusses New ESC Guidelines on Sports, Exercise in Patients With CVD
August 31st 2020The new guidelines can help cardiologists better advise patients with CVD on physical activity, said Antonio Pelliccia, MD, senior consultant and chief of cardiology at the Institute of Sports Medicine and Science, of the Italian National Olympic Committee.
Read More
Dr Manan Pareek Discusses SPRINT Trial Findings
August 31st 2020It's interesting that we saw such a clear U-shaped mortality curve for serum bicarbonate levels in a patient population where we usually don't think about measuring bicarbonate, said Manan Pareek, MD, PhD, FAHA, FESC, an internal medicine hospital resident at the Yale University School of Medicine.
Read More
Dr John McMurray Compares EMPEROR-Reduced Findings With DAPA-HF
August 31st 2020Having 2 trials that both show benefits of SGLT2 inhibitors in heart failure hospitalizations can only encourage the use of these drugs, said John McMurray, MD, FRCP, FESC, professor of medical cardiology in the Institute of Cardiovascular and Medical Sciences at the University of Glasgow.
Read More
Dr Matthew Budoff on the Benefits of Cardiac CT Use
August 31st 2020Advances in imaging have made assessment of atherosclerosis non-invasive, while the EVAPORATE trial demonstrates how cardiac CT can assist in looking at a host of different therapies, said Matthew Budoff, MD, professor of medicine at the David Geffen School of Medicine at UCLA and investigator at The Lundquist Institute.
Read More